BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 10364306)

  • 1. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
    Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
    J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
    Locher CP; Witt SA; Kassel R; Dowell NL; Fujimura S; Levy JA
    J Gen Virol; 2005 Apr; 86(Pt 4):1171-1179. PubMed ID: 15784911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
    Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
    Armand-Ugón M; Quiñones-Mateu ME; Gutiérez A; Barretina J; Blanco J; Schols D; De Clercq E; Clotet B; Esté JA
    Antivir Ther; 2003 Feb; 8(1):1-8. PubMed ID: 12713058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
    Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
    J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
    Cilliers T; Nhlapo J; Coetzer M; Orlovic D; Ketas T; Olson WC; Moore JP; Trkola A; Morris L
    J Virol; 2003 Apr; 77(7):4449-56. PubMed ID: 12634405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
    Jensen MA; Li FS; van 't Wout AB; Nickle DC; Shriner D; He HX; McLaughlin S; Shankarappa R; Margolick JB; Mullins JI
    J Virol; 2003 Dec; 77(24):13376-88. PubMed ID: 14645592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.
    Pollakis G; Abebe A; Kliphuis A; Chalaby MI; Bakker M; Mengistu Y; Brouwer M; Goudsmit J; Schuitemaker H; Paxton WA
    J Virol; 2004 Mar; 78(6):2841-52. PubMed ID: 14990703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
    Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
    J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
    Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
    AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
    Pontow S; Ratner L
    J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
    Singh A; Collman RG
    J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
    Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
    Vicenzi E; Bordignon PP; Biswas P; Brambilla A; Bovolenta C; Cota M; Sinigaglia F; Poli G
    J Virol; 1999 Sep; 73(9):7515-23. PubMed ID: 10438841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
    Stalmeijer EH; Van Rij RP; Boeser-Nunnink B; Visser JA; Naarding MA; Schols D; Schuitemaker H
    J Virol; 2004 Mar; 78(6):2722-8. PubMed ID: 14990692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressure.
    Shiino T; Kato K; Kodaka N; Miyakuni T; Takebe Y; Sato H
    J Virol; 2000 Feb; 74(3):1069-78. PubMed ID: 10627516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
    Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.